These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 39001472)

  • 1. Serial Changes of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab.
    Murata Y; Nosaka T; Akazawa Y; Tanaka T; Takahashi K; Naito T; Matsuda H; Ohtani M; Nakamoto Y
    Cancers (Basel); 2024 Jun; 16(13):. PubMed ID: 39001472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Programmed Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor and Monitor of Response to Atezolizumab plus Bevacizumab Treatment in Patients with Hepatocellular Carcinoma.
    Nosaka T; Murata Y; Akazawa Y; Tanaka T; Takahashi K; Naito T; Matsuda H; Ohtani M; Imamura Y; Nakamoto Y
    Cancers (Basel); 2024 May; 16(9):. PubMed ID: 38730737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab.
    Okuno M; Ishii T; Ichida A; Soyama A; Takemura N; Hirono S; Eguchi S; Hasegawa K; Sasaki Y; Uemura K; Kokudo N; Hatano E
    BMC Cancer; 2023 Aug; 23(1):780. PubMed ID: 37605169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case of hepatocellular carcinoma with "pseudoprogression" followed by complete response to atezolizumab plus bevacizumab.
    Odagiri N; Tamori A; Kotani K; Motoyama H; Kawamura E; Hagihara A; Fujii H; Uchida-Kobayashi S; Enomoto M; Kawada N
    Clin J Gastroenterol; 2023 Jun; 16(3):392-396. PubMed ID: 36739366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
    Eso Y; Takeda H; Taura K; Takai A; Takahashi K; Seno H
    Curr Oncol; 2021 Oct; 28(5):4157-4166. PubMed ID: 34677270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
    Chiang CL; Chan SK; Lee SF; Choi HC
    Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33668100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma.
    Tokunaga T; Tateyama M; Kondo Y; Miuma S; Miyase S; Tanaka K; Narahara S; Inada H; Kurano S; Yoshimaru Y; Nagaoka K; Watanabe T; Setoyama H; Fukubayashi K; Tanaka M; Tanaka Y
    Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events.
    Ben Khaled N; Möller M; Jochheim LS; Leyh C; Ehmer U; Böttcher K; Pinter M; Balcar L; Scheiner B; Weich A; Leicht HB; Zarka V; Ye L; Schneider J; Piseddu I; Öcal O; Rau M; Sinner F; Venerito M; Gairing SJ; Förster F; Mayerle J; De Toni EN; Geier A; Reiter FP
    JHEP Rep; 2024 Jun; 6(6):101065. PubMed ID: 38798717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Prediction of Response Focused on Tumor Markers in Atezolizumab plus Bevacizumab Therapy for Hepatocellular Carcinoma.
    Tanabe N; Saeki I; Aibe Y; Matsuda T; Hanazono T; Nishi M; Hidaka I; Kuwashiro S; Shiratsuki S; Matsuura K; Egusa M; Nishiyama N; Fujioka T; Kawamoto D; Sasaki R; Nishimura T; Oono T; Hisanaga T; Matsumoto T; Ishikawa T; Yamasaki T; Takami T
    Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor steatosis and glutamine synthetase expression in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy.
    Kurebayashi Y; Tsujikawa H; Sugimoto K; Yunaiyama D; Araki Y; Saito K; Takahashi H; Kakegawa T; Wada T; Tomita Y; Abe M; Yoshimasu Y; Takeuchi H; Hirata T; Sakamaki K; Kakimi K; Nagao T; Itoi T; Sakamoto M
    Hepatol Res; 2023 Oct; 53(10):1008-1020. PubMed ID: 37300323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of atezolizumab plus bevacizumab combination therapy for hepatocellular carcinoma using contrast-enhanced ultrasonography.
    Uchikawa S; Kawaoka T; Fujino H; Ono A; Nakahara T; Murakami E; Yamauchi M; Miki D; Imamura M; Aikata H
    J Med Ultrason (2001); 2023 Jan; 50(1):57-62. PubMed ID: 36169740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher objective responses by hepatic arterial infusion chemotherapy following atezolizumab and bevacizumab failure than when used as initial therapy in hepatocellular carcinoma: a retrospective study.
    Yoo JS; Kim JH; Cho HS; Han JW; Jang JW; Choi JY; Yoon SK; Kim S; Oh JS; Chun HJ; Sung PS
    Abdom Radiol (NY); 2024 Sep; 49(9):3127-3135. PubMed ID: 38678485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case report: Predictability of clinical response and rejection risk after immune checkpoint inhibition in liver transplantation.
    Yang Zhou J; Eder D; Weber F; Heumann P; Kronenberg K; Werner JM; Geissler EK; Schlitt HJ; Hutchinson JA; Bitterer F
    Front Transplant; 2023; 2():1211916. PubMed ID: 38993841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
    Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Matono T; Aoki T; Kuroda H; Yata Y; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Kudo M;
    Liver Int; 2024 Jan; 44(1):113-124. PubMed ID: 37789669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to atezolizumab plus bevacizumab specific for lung and lymph node metastases affects survival of patients with HCC.
    Yang J; Choi J; Choi WM; Kim KM; Lee HC; Shim JH
    Liver Int; 2024 Apr; 44(4):907-919. PubMed ID: 38291863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility of atezolizumab and bevacizumab combination regimens in patients with hepatocellular carcinoma and lung cancer taking direct oral anticoagulants.
    Nakabori T; Kunimasa K; Kawabata M; Higashi S; Mukai K; Kawamura T; Inoue T; Tamiya M; Nishino K; Ohkawa K
    Cancer Med; 2024 Jun; 13(12):e7430. PubMed ID: 38924675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve.
    Tomonari T; Tani J; Sato Y; Tanaka H; Tanaka T; Taniguchi T; Asahiro M; Okamoto K; Sogabe M; Miyamoto H; Muguruma N; Masaki T; Takayama T
    Cancer Med; 2023 Feb; 12(3):2646-2657. PubMed ID: 35964253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients.
    Mohamed YI; Duda DG; Awiwi MO; Lee SS; Altameemi L; Xiao L; Morris JS; Wolff RA; Elsayes KM; Hatia RI; Qayyum A; Chamseddine SM; Rashid A; Yao JC; Mahvash A; Hassan MM; Amin HM; Kaseb AO
    Oncotarget; 2022 Dec; 13():1314-1321. PubMed ID: 36473155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Early Progressive Disease following Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma.
    Kawamura Y; Kobayashi M; Shindoh J; Matsumura M; Okubo S; Muraishi N; Fujiyama S; Hosaka T; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Ikeda K; Arase Y; Hashimoto M; Kumada H
    Oncology; 2022; 100(6):320-330. PubMed ID: 35231914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab.
    Kikugawa C; Uchikawa S; Kawaoka T; Kinami T; Yano S; Amioka K; Naruto K; Ando Y; Yamaoka K; Tsuge M; Kosaka Y; Ohya K; Mori N; Takaki S; Tsuji K; Kouno H; Kohno H; Morio K; Moriya T; Nonaka M; Aisaka Y; Masaki K; Honda Y; Naeshiro N; Hiramatsu A; Aikata H; Oka S
    Oncology; 2024; 102(3):239-251. PubMed ID: 37729889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.